Table 1.

Summary baseline clinicopathological characteristics of the study cohort. The p-values are presented for an intergroup comparison between progressors and non-progressors performed using the Mann-Whitney U test. AS, active surveillance; PSA, prostate-specific antigen

Parameter	Total cohort (n = 64)	Progressors (n = 27)	Non-progressors (n = 37)	p-value
Age, years	67 (60–69)	66 (60–69)	67 (61–69)	0.9218
PSA, ng/mL	5.6 (3.6–7.7)	7.0 (5.2–8.7)	5.0 (3.17–6.9)	0.0102
Gland volume, mL	45.0 (33.0–63.8)	45.0 (29.0–52.0)	45.0 (36.6–66.2)	0.1851
PSA density	0.11 (0.08–0.19)	0.17 (0.11–0.27)	0.09 (0.06–0.16)	0.0024
AS follow-up, mo	46 (35–52)	43 (24–49)	47 (44–60)	0.0093
Biopsy grade group 1 (3 + 3 = 6), n	51 (78%)	23 (85%)	28 (74%)	-
Biopsy grade group 2 (3 + 4 = 7), n	14 (22%)	4 (15%)	10 (26%)
Target lesion in the peripheral zone, n	46 (70%)	17 (63%)	29 (76%)	-
Target lesion in the transition zone, n	19 (30%)	10 (27%)	9 (24%)